AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
6 Department of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai, China
7 Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co.Ltd, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, 200025 Shanghai, China; Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background
Adult T-cell acute lymphoblastic leukemia (T-ALL) remains a biologically heterogeneous disease with suboptimal outcomes under conventional intensive chemotherapy. Early achievement of measurable residual disease (MRD) negativity after induction therapy is a key prognostic factor for long-term survival. Venetoclax, a selective BCL-2 inhibitor, has demonstrated promising antileukemic activity in lymphoid malignancies. However, prospective data on venetoclax-based regimens in newly diagnosed adult T-ALL are still limited.
Aims
To define the efficacy (MRD negativity rate) and safety profile of venetoclax in combination with pediatric-inspired multi-drug chemotherapy in newly diagnosed adult T-ALL.
Methods
This is an ongoing, multicenter, phase II prospective clinical trial (ChiCTR2400086542) evaluating the efficacy and safety of venetoclax in combination with a pediatric-inspired chemotherapy regimen in adults with newly diagnosed T-ALL. Induction therapy consisted of vincristine, idarubicin, prednisone/prednisolone, cyclophosphamide and pegaspargase. Venetoclax was administered orally with a ramp-up schedule of 100 mg on day 4, 200 mg on day 5, and 400 mg from day 6 to day 14 during induction. Patients with poor early response, defined as day 14 bone marrow blasts >25% (M3 marrow), continued venetoclax at 400 mg daily until day 21. During the consolidation phase, venetoclax (400 mg on days 1–7) was combined with alternating hyper-CVAD courses A and B. High-risk T-ALL patients with suitable donors were planned to proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT) after achieving MRD negativity.
Primary endpoint was MRD negativity after induction therapy. Secondary endpoints included complete remission (CR) rate, overall survival (OS), event-free survival (EFS) and allo-HSCT rate.
Multiparameter flow cytometry was employed for MRD monitoring, negative MRD was defined as less than 0.01% (MRD<10-4). Safety assessments included the evaluation of adverse events, which were graded according to CTCAE (version 5.0).
Results
Between August 2024 and April 2026, 34 patients were enrolled, and 28 were evaluable. The median age was 33.5 years (range, 17–62), 60.7% (n=17) were male, and 46.4% (n=13) had early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Five patients received extended venetoclax for 21 days during induction.
After one induction cycle, the overall response rate (ORR, defined as complete remission [CR] or CR with incomplete peripheral blood count recovery [CRi]) was 85.7% (24/28). Similar response rates were observed between ETP-ALL and non-ETP ALL (92.3% [12/13] vs. 80.0% [12/15], respectively; p=0.6). Among the 24 patients achieving CR/CRi, 18 (75.0%) achieved MRD negativity, with identical MRD clearance rates observed in ETP-ALL and non-ETP ALL (9/12 [75.0%] vs. 9/12 [75.0%], respectively; p=1.0). Sixteen patients (57.1%) subsequently proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). During follow-up, six patients experienced relapse, including four relapses occurring before allo-HSCT and two after transplantation. Notably, both post-transplant relapses occurred in patients who underwent allo-HSCT with persistent MRD positivity, while no relapse was observed after allo-HSCT among patients who achieved MRD negativity.
As of the last follow-up (June 20, 2026), all patients were alive except for one patient who died during the consolidation phase due to concomitant autoimmune encephalitis. The median follow-up duration was 12.5 months (range: 2.4-23.5 months), the median EFS and OS were not reached, with estimated 1-year EFS and OS rates of 75.5% (95% CI 66.7%-84.3%) and 95.7% (95% CI 91.4%-100%), respectively.
The most frequent all-grade adverse events were leukocytopenia and thrombocytopenia (100%). Median times to platelet and neutrophil recovery were 23 days and 18 days, respectively. Only one patient (1/28, 4.3%) developed tumor lysis syndrome, which resolved after symptomatic treatment. No early mortality (within 30 days of treatment initiation) was observed.
Conclusion
These interim results the combination of venetoclax and pediatric-inspired chemotherapy induced deep responses in newly diagnosed adult T-ALL, with substantial MRD clearance observed across both ETP and non-ETP subgroups. Favorable early EFS and OS outcomes suggest this regimen may represent a promising approach for improving remission depth and facilitating curative-intent therapy.